Low-Molecular-Weight Heparin-Induced Thrombocytopenia in a Child

Annals of Pharmacotherapy

Volumn 38, Issue 2, 2004, Pages 247-250

  Dager, William E ^a,b,c   White, Richard H ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Enoxaparin; Heparin induced thrombocytopenia; Lepirudin; Low molecular weight heparin; Warfarin

Indexed keywords

ANTIBODY; D DIMER; ENOXAPARIN; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PLATELET FACTOR 4 ANTIBODY; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; WARFARIN;

AFRICAN AMERICAN; ARTICLE; CASE REPORT; CAVA VEIN DISEASE; CAVA VEIN THROMBOSIS; COLONOSCOPY; CROHN DISEASE; DEEP VEIN THROMBOSIS; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS;

ANTICOAGULANTS; CHILD; ENOXAPARIN; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; PLATELET COUNT; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 1542273168     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D308     Document Type: Article

References (22)

1. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000:96:1703-8.
2. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med 1996:101:502-7.
3. Schmugge M, Risch L, Huber AR, Benn A, Fischer JE. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002;109:E10.
4. Newall F, Barnes C, Ignjatovic V, Monagle P. Heparin-induced thrombocytopenia in children. J Paediatr Child Health 2003:39:289-92.
5. Neuhaus TJ, Goetschel P, Schmugge M, Leumann E. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid. Pediatr Nephrol 2000;14:713-6.
6. Wilhelm MJ, Schmid C, Kececioglu D, Mollhoff T, Ostermann H, Scheld HH. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using ORG 10172. Ann Thorac Surg 1996;61:920-4.
7. Klement D, Rammos S, von Kries R, Kirschke W, Kniemeyer HW, Greinacher A. Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr 1996;155:11-4.
8. Saxon BR, Black MD, Edgell D, Noel D, Leaker MT. Pediatric heparin-induced thrombocytopenia: management with danaparoid (Orgaran). Ann Thorac Surg 1999;68:1076-8.
9. Zohrer B, Zenz W, Rettenbacher A, Covi P, Kurnik K, Kroll H, et al. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II. Acta Paediatr 2001;90:765-71.
10. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients - a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999;158(suppl 3):S130-3.
11. Dager WE, White RH. Pharmacotherapy of heparin-induced thrombocytopenia. Expert Opin Pharmacother 2003;4:919-40.
12. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-55.
13. Boshkov LK, Thomas G, Kirby A, Shen I, Swanson V, Burch G, et al. Pharmacokinetics of argatroban infusion in a 6 month old congenital cardiac patient with previously diagnosed heparin-induced thrombocytopenia (HIT) (abstract). Blood 2002;100:269a.
14. Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 2000;14:445-57.
15. Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem 1999;45:409-12.
16. Yonekawa KE, Nugent DJ, Young G. Use of bivalirudin for anticoagulation of a neonatal extracorporeal membranous oxygenation (ECMO) circuit (abstract). Blood 2002;100:129b.
17. Schiffman, Unterhalt M, Harms K, Figulla HR, Volpel H, Greinacher A. [Successful treatment of heparin-induced thrombocytopenia (HIT) type II in childhood with recombinant hirudin.] German. Monatsschr Kinderheilkd 1997;145:606-12.
18. Prescribing information. Refludan (lepirudin (rDNA) for injection). Wayne, NJ: Berlex Laboratories.
19. Nguyen TN, Gal P, Ransom JL, Carlos R. Lepirudin Use in a neonate with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:229-33. DOI 10.1345/aph.IC224
20. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
21. Lubenow N, Eicher P, Lietz T, Greinacher A. Meta-analysis of the three prospective studies of lepirudin in the prevention of thrombosis in patients with heparin-induced thrombocytopenia (abstract). Blood 2002;100:501a-2b.
22. Vanholder R, Camez A, Veys N, van Loo A, Dhondt AM, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 1997;77:650-5.